Federal Drug Price Reforms Are Working, Study Says

Why It Matters

The findings validate federal price controls as a lever to improve drug adherence, a key driver of health outcomes and long‑term cost containment in the Medicare system.

Key Takeaways

• IRA cuts Medicare drug co‑insurance, capping out‑of‑pocket costs.
• Medication nonadherence fell 4.9 percentage points among seniors.
• Patients with multiple chronic conditions saw 7.8 pp improvement.
• 1.5 million beneficiaries saved nearly $1 billion in 2024.
• No measurable reduction in overall Medicare spending yet.

Pulse Analysis

The Inflation Reduction Act marked a watershed moment for U.S. drug policy, targeting the two most vulnerable Medicare groups: high‑spending seniors and low‑income enrollees. By removing the 5 percent co‑insurance for catastrophic coverage and expanding full subsidies, the law aimed to cap out‑of‑pocket expenses around $3,300 annually. This structural shift reflects a broader federal effort to curb prescription‑drug inflation and align patient costs with the value of essential therapies.

Empirical evidence now supports the act’s early promise. Using a quasi‑experimental difference‑in‑differences design, researchers compared Medicare Part D participants aged 62‑67 with a privately insured control cohort. The analysis revealed a 4.9‑percentage‑point reduction in cost‑related medication nonadherence, with an even sharper 7.8‑point decline for beneficiaries managing multiple chronic illnesses such as diabetes and heart disease. Financially, the policy translated into nearly $1 billion in savings for 1.5 million seniors by mid‑2024, underscoring how targeted price caps can directly alleviate out‑of‑pocket burdens.

While adherence gains are encouraging, the study also highlights limits. No significant change emerged in overall Medicare expenditures or patients’ ability to meet other medical bills, suggesting that drug‑price reforms alone may not offset broader health‑care cost pressures. Policymakers will likely need complementary measures—such as value‑based pricing, expanded preventive care, and tighter negotiation authority—to translate adherence improvements into measurable savings across the system. For industry stakeholders, the data signal a shifting landscape where price transparency and patient affordability are becoming central performance metrics.